◆英語タイトル:Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8010770
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月20日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Biofrontera AG (B8F) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops dermatological medicine and products. The company’s products comprise ameluz, BF-RhodoLED and belixos. Its prescription drug ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera’s BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. The company’s cosmeceutical line of products, belixos is used for regenerative care of reddened and inflamed skin. Its belixos line of products include belixos creme, belixos liquid, belixos gel, belixos to go and belixos protect. The company’s pipeline products include BF-1 and BF-derm1. It operates in the US and Germany. Biofrontera is headquartered in Leverkusen, Germany.
Biofrontera AG Key Recent Developments
Nov 27,2017: Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017
Nov 14,2017: Biofrontera adjusts revenues and earnings forecast for the financial year 2017
Oct 16,2017: Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference
Aug 31,2017: Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
Aug 31,2016: Biofrontera Reports Financial Results and Business Update for Second Quarter and First Half 2016
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Biofrontera AG – Key Facts 5
Biofrontera AG – Key Employees 6
Biofrontera AG – Key Operational Employees 7
Biofrontera AG – Major Products and Services 8
Biofrontera AG – History 9
Biofrontera AG – Company Statement 10
Biofrontera AG – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Biofrontera AG – Business Description 14
R&D Overview 14
Biofrontera AG – Corporate Strategy 15
Biofrontera AG – Strengths 16
Biofrontera AG – Weaknesses 17
Biofrontera AG – Opportunities 18
Biofrontera AG – Threats 19
Biofrontera AG – Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios – Capital Market Ratios 20
Financial Ratios – Annual Ratios 21
Performance Chart 23
Financial Performance 23
Financial Ratios – Interim Ratios 24
Financial Ratios – Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 26
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Biofrontera AG, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Nov 27, 2017: Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017 29
Nov 14, 2017: Biofrontera adjusts revenues and earnings forecast for the financial year 2017 31
Oct 16, 2017: Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference 32
Aug 31, 2017: Biofrontera Grows Revenues and Improves Financial Position in First Half 2017 33
Aug 31, 2016: Biofrontera Reports Financial Results and Business Update for Second Quarter and First Half 2016 35
Jun 02, 2016: Biofrontera Announces Appointment of Four New Supervisory Board Members 37
May 25, 2016: Biofrontera Reports First Quarter 2016 Financial Results and Business Update 38
Apr 15, 2016: Biofrontera Reports Full Year 2015 Financial Results 40
Section 6 – Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Biofrontera AG, Key Facts 5
Biofrontera AG, Key Employees 6
Biofrontera AG, Key Operational Employees 7
Biofrontera AG, Major Products and Services 8
Biofrontera AG, History 9
Biofrontera AG, Subsidiaries 13
Biofrontera AG, Key Competitors 19
Biofrontera AG, Ratios based on current share price 20
Biofrontera AG, Annual Ratios 21
Biofrontera AG, Annual Ratios (Cont...1) 22
Biofrontera AG, Interim Ratios 24
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 26
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Biofrontera AG, Recent Deals Summary 28
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44